NXTC · NextCure, Inc.
$4.24
+0.06 (+1.44%)
At close · Jul 24
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our expectation to incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued.”View the 10-Q filed May 7, 2026
Market Cap
$15.32M
Shares
3.61M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $941,692 |
| Udayan Guha | Chief Medical Officer | $639,239 |
| Timothy Mayer | COO | $633,181 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $1,510,939 |
| Solomon Langermann | Chief Scientific Officer | $882,845 |
| Han Myint | M.D., FACP Chief Medical Officer | $874,322 |
| Timothy Mayer | COO | $872,206 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $1,044,627 |
| Han Myint | M.D., FACP Chief Medical Officer | $697,932 |
| Solomon Langermann | Chief Scientific Officer | $681,586 |
| Sol Langerman. Ph.D | Chief Scientific Officer | $681,586 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $1,724,186 |
| Sol Langermann | Chief Scientific Officer | $990,524 |
| Sol Langerman. Ph.D | Chief Scientific Officer | $990,524 |
| Han Myint | M.D., FACP Chief Medical Officer | $953,318 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $3,321,425 |
| Han Myint | M.D., FACP Chief Medical Officer | $2,261,982 |
| Sol Langermann | Chief Scientific Officer | $1,392,982 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $6,488,396 |
| Kevin Heller | Chief Medical Officer | $2,838,459 |
| Sol Langermann | Chief Scientific Officer | $2,484,687 |
| James B. Bingham | Chief Development Officer | $2,447,482 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $625,679 |
| Kevin Heller | Chief Medical Officer | $505,294 |
| Sol Langermann | Chief Scientific Officer | $459,105 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Richman | CEO | $2,501,597 |
| Sol Langermann | Chief Scientific Officer | $882,291 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John G. Houston, PH.D. | Class I Director | Appointed | 2026-06-25 |
| Anne Borgman, M.D. | Class I Director | Appointed | 2026-06-25 |